VI治療失敗時の薬剤変更

文献

  1. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 15:1369-77.2001.
  2. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 293: 817-29, 2005
  3. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 16: 2035-41, 2002.
  4. Martinez V, Marcelin AG, Morini JP, et al. HIV-1 intermittent viraemia in patients treated by nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS. 19: 1065-9, 2005.
  5. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 286: 171-9, 2001.
  6. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 18: 981-9, 2004.
  7. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 286: 196-20, 2001.
  8. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 33: 75-8, 2005.
  9. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (米国DHHS、October 25, 2018).
    https://www.aidsinfo.nih.gov/よりダウンロード可能
  10. harles H, Eron J., Fiscus S., et al. Transmitted HIV Resistance among Patients with Acute and Recent HIV Infection in North Carolina: Report of 102 Cases. 12th CROI abstract #673, 2005.
  11. Wensing AM, van de Vijver DA, Angarano G. et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 192: 958-66, 2005.
  12. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationawide surveillance from 2003 to 2008 in Japan. Antiviral Res. 88: 72-9, 2010.
  13. King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy- naïve patients. J Infect Dis. 190: 280-4, 2004.
  14. HIV診療における外来チーム医療マニュアル改訂第2版(厚生労働行政推進調査事業費補助金(エイズ対策政策研究事業)「HIV感染症及びその合併症の課題を克服する研究」班):https://www.haart-support.jp/manual/index.htm
  15. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 16: 209-18, 2002.
  16. Stanford HIV RT and Protease Sequence Database (https://hivdb.stanford.edu/)
  17. R. Stryker, S. Brun, M. King, et al. Kaletra (ABT-378/ritonavir) in Antiretroviral- naïve HIV+ Patients: Follow-up Beyond Two Years and Viral Load Suppression Below 3 Copies/m. 5TH INTERNATIONAL CONGRESS ON DRUG THERAPY IN HIV INFECTION, 2000.
  18. Hattori J, Shiino T, Gatanaga H, et al. Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment - Naïve Patients in Japan. J Acquir Immune Defic Syndr. 71:367-73.2016.
  19. HIV薬剤耐性検査ガイドラインver.10 (日本医療研究開発機構エイズ対策実用化研究事業「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班):https://www.hiv-resistance.jp/resistance04.htm
  20. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47; 3123-9, 2003.
  21. Meyer SD, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49; 2314-21, 2005.
  22. Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 39; 28709-20, 2007.
  23. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 369; 1169-78, 2007.
  24. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonvir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet 370; 49-58, 2007.
  25. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370; 29-38, 2007.
  26. Lazzarin A, Campbell T, Clotet B, J et al. Efficacy and safety of TMC125 (etravirine) in treatment experienced HIV-1-infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370; 39-48, 2007.
  27. Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. Int Cong Drug Therapy, Nov. 12-16, 2006. Vol.8. Abstract PL5.6.
  28. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized Background therapy for resistant HIV-1 infection. N Engl J Med 359;339-54, 2008.
  29. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N Engl J Med 359;355-65, 2008.
  30. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 49;1441-9. 2009
  31. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavirritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet.375;396-407, 2010.
  32. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet. 381;735-43, 2013.
  33. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369;1807-18, 2013.
  34. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegraivr versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet. 382:700-8, 2014.
  35. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral experienced patients with raltegravir- and/or elvitegravirresistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 210:354-62, 2014.
  36. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week redults of a phase 2b explatory trial. 16th IAC Abstract THLB0215, 2006.

PAGE TOP

アンケートにご協力ください。

このページは役に立ちましたか?

コメント